Cell Death Dis:研究发现二甲双胍对食道癌作用机制

2014-03-17 中国科学报 中国科学报

据从汕头大学获悉,该校医学院教授张灏带领的课题组发现了抗糖尿病药物二甲双胍对人类食道癌的作用机制并进行了临床前研究。相关成果日前在线发表于自然集团所属期刊《细胞死亡及疾病》。 该课题组从临床问题出发提出了科学假说:二甲双胍可能在不同肿瘤中通过作用于不同肿瘤特有的个性化分子靶点发挥作用,而阐明相应的个性化靶点有助于优化设计针对不同肿瘤的治疗方案。 课题组在分子、细胞、整体(动物模型)和病人标本等

据从汕头大学获悉,该校医学院教授张灏带领的课题组发现了抗糖尿病药物二甲双胍对人类食道癌的作用机制并进行了临床前研究。相关成果日前在线发表于自然集团所属期刊《细胞死亡及疾病》。【原文下载】

该课题组从临床问题出发提出了科学假说:二甲双胍可能在不同肿瘤中通过作用于不同肿瘤特有的个性化分子靶点发挥作用,而阐明相应的个性化靶点有助于优化设计针对不同肿瘤的治疗方案。

课题组在分子、细胞、整体(动物模型)和病人标本等多个水平详细阐述了相关的科学问题。他们发现,二甲双胍可选择性地抑制食道鳞状细胞癌细胞的生长,除能诱导凋亡性细胞死亡和抑制细胞增殖外,还能诱发自噬。而通过药物或基因水平抑制自噬,可使肿瘤细胞对二甲双胍诱导的凋亡性死亡更加敏感。

食道鳞状细胞癌是一种炎症性恶性肿瘤,而Stat3基因产物是许多癌症基因和炎性信号通路的交汇点。张灏课题组所作的分子机制研究发现,二甲双胍治疗使Stat3通路特别是Stat3-Bcl2-Beclin1网络信号通路失活,促进细胞凋亡和自噬之间的串扰,引起了二甲双胍对肿瘤的生长抑制。

目前,课题组计划扩展研究并设计临床试验开展二甲双胍对食管癌的干预治疗。

原始出处:

Feng Y1, Ke C2, Tang Q1, Dong H2, Zheng X2, Lin W2, Ke J1, Huang J3, Yeung SC4, Zhang H5.Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling.Cell Death Dis. 2014 Feb 27;5:e1088. doi: 10.1038/cddis.2014.59.【原文下载】

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=37841, encodeId=d8be3e8419e, content=二甲双胍抗肿瘤新机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014b25346, createdName=tswj126, createdTime=Wed Oct 07 16:40:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753059, encodeId=d6681e53059ff, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Sep 29 00:31:00 CST 2014, time=2014-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011876, encodeId=8d4c20118e63b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Apr 09 03:31:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959031, encodeId=313619590316a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 27 14:31:00 CST 2014, time=2014-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868789, encodeId=b9661868e898a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 18 16:31:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531380, encodeId=37f41531380f5, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Wed Mar 19 02:31:00 CST 2014, time=2014-03-19, status=1, ipAttribution=)]
    2015-10-07 tswj126

    二甲双胍抗肿瘤新机制

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=37841, encodeId=d8be3e8419e, content=二甲双胍抗肿瘤新机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014b25346, createdName=tswj126, createdTime=Wed Oct 07 16:40:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753059, encodeId=d6681e53059ff, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Sep 29 00:31:00 CST 2014, time=2014-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011876, encodeId=8d4c20118e63b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Apr 09 03:31:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959031, encodeId=313619590316a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 27 14:31:00 CST 2014, time=2014-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868789, encodeId=b9661868e898a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 18 16:31:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531380, encodeId=37f41531380f5, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Wed Mar 19 02:31:00 CST 2014, time=2014-03-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=37841, encodeId=d8be3e8419e, content=二甲双胍抗肿瘤新机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014b25346, createdName=tswj126, createdTime=Wed Oct 07 16:40:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753059, encodeId=d6681e53059ff, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Sep 29 00:31:00 CST 2014, time=2014-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011876, encodeId=8d4c20118e63b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Apr 09 03:31:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959031, encodeId=313619590316a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 27 14:31:00 CST 2014, time=2014-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868789, encodeId=b9661868e898a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 18 16:31:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531380, encodeId=37f41531380f5, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Wed Mar 19 02:31:00 CST 2014, time=2014-03-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=37841, encodeId=d8be3e8419e, content=二甲双胍抗肿瘤新机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014b25346, createdName=tswj126, createdTime=Wed Oct 07 16:40:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753059, encodeId=d6681e53059ff, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Sep 29 00:31:00 CST 2014, time=2014-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011876, encodeId=8d4c20118e63b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Apr 09 03:31:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959031, encodeId=313619590316a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 27 14:31:00 CST 2014, time=2014-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868789, encodeId=b9661868e898a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 18 16:31:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531380, encodeId=37f41531380f5, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Wed Mar 19 02:31:00 CST 2014, time=2014-03-19, status=1, ipAttribution=)]
    2014-09-27 维他命
  5. [GetPortalCommentsPageByObjectIdResponse(id=37841, encodeId=d8be3e8419e, content=二甲双胍抗肿瘤新机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014b25346, createdName=tswj126, createdTime=Wed Oct 07 16:40:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753059, encodeId=d6681e53059ff, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Sep 29 00:31:00 CST 2014, time=2014-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011876, encodeId=8d4c20118e63b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Apr 09 03:31:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959031, encodeId=313619590316a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 27 14:31:00 CST 2014, time=2014-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868789, encodeId=b9661868e898a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 18 16:31:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531380, encodeId=37f41531380f5, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Wed Mar 19 02:31:00 CST 2014, time=2014-03-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=37841, encodeId=d8be3e8419e, content=二甲双胍抗肿瘤新机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014b25346, createdName=tswj126, createdTime=Wed Oct 07 16:40:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753059, encodeId=d6681e53059ff, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Sep 29 00:31:00 CST 2014, time=2014-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011876, encodeId=8d4c20118e63b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Apr 09 03:31:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959031, encodeId=313619590316a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 27 14:31:00 CST 2014, time=2014-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868789, encodeId=b9661868e898a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 18 16:31:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531380, encodeId=37f41531380f5, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Wed Mar 19 02:31:00 CST 2014, time=2014-03-19, status=1, ipAttribution=)]
    2014-03-19 cy0328

相关资讯

Diabetes Care:二甲双胍与膀胱癌发病降低无关

美国一项研究表明,二甲双胍与膀胱癌发病率降低无相关性。研究者建议,应用与该研究相同的方法去研究之前报道的二甲双胍对其他癌症的潜在预防作用。文章2月4日在线发表于《糖尿病护理》(Diabetes Care)杂志。 既往评估二甲双胍对癌症风险影响的研究受时间相关偏差的影响,为避免这些偏差,研究者在二甲双胍和磺脲类降糖药(SUs)的起始应用者中评估了膀胱癌的发病率。 该队列研究纳入健康改善网

Lancet Diab & Endo:二甲双胍在非糖尿病人群中心血管获益有限

研究要点:该研究评估二甲双胍对非2型糖尿病个体心血管的影响;二甲双胍对非糖尿病个体cIMT和颈动脉斑块评分几乎没有影响;二甲双胍可以显著降低HbA1c、HOMA–IR和组织型纤溶酶原激活物;二甲双胍整体不良事件发生率与安慰剂组相似,但消化道症状更常见。二甲双胍降低2型糖尿病患者心血管风险似乎与血糖浓度的降低无关。为了评估二甲双胍对非2型糖尿病个体心血管的影响,来自英国格拉斯哥大学David Pre

EMA推荐糖尿病新药Vokanamet(SGLT-2阻断剂)上市

2月20日,欧洲药品管理局(EMA)人用医药产品委员会(CHMP)推荐糖尿病治疗药物Vokanamet(活性成分为Canagliflozin和二甲双胍)授权上市。 Vokanamet适用于最大耐受剂量二甲双胍仍无法充分控制血糖水平的成人2型糖尿病患者,最大耐受剂量二甲双胍与包括胰岛素在内的其他降糖药联用仍无法充分控制血糖者,以及canagliflozin和二甲双胍单独片剂疗效不佳者。 Voka

JNCI:二甲双胍治疗不影响糖尿病患者前列腺癌的发病风险

研究要点: 动物模型实验提示二甲双胍具有一定的抗肿瘤作用。 二甲双胍对前列腺癌的预防作用结论不一。 本研究结果证实在患有糖尿病的前列腺癌病人中,二甲双胍对前列腺癌的发病风险无显著影响。 二甲双胍是治疗2型糖尿病的常用药物。最近有证据显示二甲双胍或具有抗肿瘤的作用。因此,加拿大多伦多健康网络大学David Margel等设计了相关研究,目的在于评价在患有糖尿病的男性病人中,二甲双胍应用和前列

NRR:二甲双胍抑食作用的中枢机制

脑功能基因组学教育部重点实验室的赵政教授领导的团队提出在正常生理条件下,观察二甲双胍对大脑(下丘脑)作用后引起的饮食行为学变化,并据此进行了一项关于“Metformin inhibits food intake and neuropeptide Y gene expression in the hypothalamus”的研究。【原文下载】结果发现,二甲双胍经第三脑室给药可显著减少摄食量和

Lancet Diab & Endo:2型糖尿病初始治疗阿卡波糖不劣于二甲双胍(MARCH研究)

  中日友好医院内分泌科杨文英教授主持的一项研究显示,在中国新诊断的2型糖尿病患者中,阿卡波糖的疗效非劣于二甲双胍。该研究10月18日在线发表于The Lancet Diabetes & Endocrinology杂志,这是一项非劣效研究。    由于二甲双胍的疗效、 安全性和成本效益已被证实,因此目前多家指南将二甲双胍作为治疗2型糖尿病的唯一一线口服降